Drugs.com Clinical Trial ResultsOriginal article
Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer
RegulatoryPIKTOR Plus PaclitaxelPositive
AI Analysis
Summary
Faeth Therapeutics announced FDA Fast Track Designation for PIKTOR Plus Paclitaxel in biomarker-selected advanced endometrial cancer. Fast Track status expedites development and review of the investigational therapy.
Outcome Details
FDA granted Fast Track Designation
Importance:6/10
Sentiment:
0.70
FDAFast Track DesignationOncologyEndometrial CancerPIKTOR
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on August 17, 2026 10:08 PM